Mavrilimumab

Mavrilimumab is a human monoclonal antibody^[1] that inhibits human granulocyte macrophage colony-stimulating factor receptor (GM-CSF-R).^[2]

Mavrilimumab

Monoclonal antibody
Type	Whole antibody
Source	Human
Target	GM-CSF receptor alpha chain
Clinical data
ATC code	none
Identifiers
CAS Number	1085337-57-0 N
IUPHAR/BPS	7785
ChemSpider	none
UNII	1158JD1P9A
Chemical and physical data
Formula	C6706H10438N1762O2104S54
Molar mass	151140.74 g·mol−1
NY (what is this?)  (verify)

Mavrilimumab was discovered as CAM-3001 by Cambridge Antibody Technology and is being developed by MedImmune, Inc.^[1] as an investigational drug for the treatment of rheumatoid arthritis

Mavrilimumab has been studied in a phase 1 dose-ranging trial^[2] and a phase 2a clinical trial, both sponsored by Medimmune.^[3] The phase 2a trial, which studied mavrilimumab doses of up to 100 mg, reported that 55.7% of subjects met the primary endpoint of a ≥1.2 decrease from baseline in disease activity scores at week 12 (vs. only 34.7% of placebo subjects).^[3]

In 2013, two further clinical studies were reported to be underway in rheumatoid arthritis patients to investigate these effects further.^[4]

In early 2017 the phase IIb study was reported to be showing promising results.^[5]

In 2017, Kiniksa licensed Mavrilimumab from MedImmune.^[6]

It was studied in 2020 to see if it could improve the prognosis for patients with COVID-19 pneumonia and systemic hyperinflammation. One small study indicated some beneficial effects of treatment with mavrilimumab compared with those who were not.^[7]

In April 2021, Kiniksa outlined the next steps for development of Mavrilimumab - including in COVID-19–related acute respiratory distress syndrome (ARDS), giant cell arteritis (GCA), and rheumatoid arthritis (RA). “Recent favorable interactions with the FDA, based upon the clinical data generated with mavrilimumab in COVID-19-related ARDS, giant cell arteritis, and rheumatoid arthritis, underscore the broad utility of mavrilimumab and define a regulatory pathway for Phase 3 clinical development for each indication,” said Sanj K. Patel, Chief Executive Officer and Chairman of the Board of Kiniksa. “We believe the ongoing Phase 3 study of mavrilimumab in COVID-19-related ARDS represents the fastest path to potential registration for the asset, and there remains a significant unmet need in these patients. Enrollment in our Phase 3 clinical trial is ongoing, and we expect data in the first quarter of 2022.”.^[8]